SCHEMBL25754754

SCHEMBL25754754

CC#CC(=O)CCOCCCNCCN1CCCCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 5/20 0.35
HRH3 Q9Y5N1 3/20 0.35
THRB P10828 3/20 0.35
CYP1A2 P05177 2/20 0.35
LMNA P02545 2/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
ADRA2C P18825 1/20 0.35
DRD4 P21917 1/20 0.35
ACHE P22303 1/20 0.35
SLC6A2 P23975 1/20 0.35
HRH2 P25021 1/20 0.35
HTR2A P28223 1/20 0.35
ADRA1A P35348 1/20 0.35
HRH1 P35367 1/20 0.35
SLC6A3 Q01959 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754752 0.90 SMN1; SMN2 (0.38) ALDH1A1HRH3THRBCYP1A2LMNA
SCHEMBL25754725 0.89 KMT2A (0.36) KMT2AALDH1A1HRH3THRBCYP1A2
SCHEMBL25754758 0.85 HRH3 (0.39) HRH3CYP1A2CHRM2ADRA2CSLC6A2
SCHEMBL25754613 0.84 HRH3 (0.42) ALDH1A1HRH3THRBCYP1A2SMN1; SMN2
SCHEMBL25754691 0.84 NPC1 (0.41) KMT2AALDH1A1CYP1A2SMN1; SMN2MAPK1
SCHEMBL25754731 0.84 KDM4E (0.39) KMT2AALDH1A1HRH3CYP1A2SMN1; SMN2
SCHEMBL25754712 0.81 KMT2A (0.38) KMT2AALDH1A1NPC1MAPTCA12
SCHEMBL25754710 0.80 CYP1A2 (0.42) ALDH1A1HRH3CYP1A2SMN1; SMN2MAPK1
SCHEMBL25754594 0.80 CYP1A2 (0.42) ALDH1A1HRH3THRBCYP1A2LMNA
SCHEMBL25754610 0.79 HRH3 (0.42) ALDH1A1HRH3THRBCYP1A2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 KMT2A 1974/4885ALDH1A1 2539/4885HRH3 1596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.